Does the media favor EWTX or ASND?

In the previous week, Ascendis Pharma A/S had 20 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Ascendis Pharma A/S's score of 0.68 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 7 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BBIO or EWTX?

In the previous week, BridgeBio Pharma had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for BridgeBio Pharma and 3 mentions for Edgewise Therapeutics. BridgeBio Pharma's average media sentiment score of 0.87 beat Edgewise Therapeutics' score of 0.75 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EWTX or EXEL?

In the previous week, Exelixis had 12 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 15 mentions for Exelixis and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Exelixis' score of 0.44 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SMMT or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is SMMT or EWTX more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Edgewise Therapeutics N/A -39.01% -36.96%

Does the media favor SMMT or EWTX?

In the previous week, Summit Therapeutics had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 7 mentions for Summit Therapeutics and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Summit Therapeutics' score of 0.20 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMRN or EWTX?

In the previous week, BioMarin Pharmaceutical had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat BioMarin Pharmaceutical's score of 0.64 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Edgewise Therapeutics (EWTX) Competitors

$45.32 -1.62 (-3.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$44.85 -0.47 (-1.04%)

As of 09/18/2026 07:30 PM Eastern

Compare

EWTX vs. ASND, BBIO, EXEL, SMMT, and BMRN

Should you buy Edgewise Therapeutics stock or one of its competitors? Edgewise Therapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Exelixis (EXEL), Summit Therapeutics (SMMT), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Edgewise Therapeutics (NASDAQ:EWTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

In the previous week, Ascendis Pharma A/S had 20 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Ascendis Pharma A/S's score of 0.68 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	7 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics currently has a consensus target price of $50.33, indicating a potential upside of 11.06%. Ascendis Pharma A/S has a consensus target price of $310.75, indicating a potential upside of 31.27%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Edgewise Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Ascendis Pharma A/S	$814.57M	18.13	-$258M	$12.89	18.36

Ascendis Pharma A/S has a net margin of 70.99% compared to Edgewise Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Edgewise Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Edgewise Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Edgewise Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

BridgeBio Pharma presently has a consensus price target of $102.61, indicating a potential upside of 54.05%. Edgewise Therapeutics has a consensus price target of $50.33, indicating a potential upside of 11.06%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Edgewise Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.94	-$724.93M	-$3.57	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, BridgeBio Pharma had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for BridgeBio Pharma and 3 mentions for Edgewise Therapeutics. BridgeBio Pharma's average media sentiment score of 0.87 beat Edgewise Therapeutics' score of 0.75 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Summary

BridgeBio Pharma beats Edgewise Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Exelixis?

Edgewise Therapeutics (NASDAQ:EWTX) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Edgewise Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Edgewise Therapeutics presently has a consensus price target of $50.33, indicating a potential upside of 11.06%. Exelixis has a consensus price target of $50.29, indicating a potential downside of 13.84%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Edgewise Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Exelixis has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.35

Exelixis has a net margin of 35.33% compared to Edgewise Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Exelixis	35.33%	42.17%	31.76%

85.3% of Exelixis shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Exelixis had 12 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 15 mentions for Exelixis and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Exelixis' score of 0.44 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Exelixis beats Edgewise Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

In the previous week, Summit Therapeutics had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 7 mentions for Summit Therapeutics and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat Summit Therapeutics' score of 0.20 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.24, indicating that its stock price is 224% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Edgewise Therapeutics' return on equity of -39.01% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Summit Therapeutics presently has a consensus target price of $25.91, suggesting a potential upside of 45.14%. Edgewise Therapeutics has a consensus target price of $50.33, suggesting a potential upside of 11.06%. Given Summit Therapeutics' higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Edgewise Therapeutics beats Summit Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Edgewise Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Edgewise Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

BioMarin Pharmaceutical currently has a consensus target price of $89.17, indicating a potential upside of 39.46%. Edgewise Therapeutics has a consensus target price of $50.33, indicating a potential upside of 11.06%. Given BioMarin Pharmaceutical's higher probable upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

BioMarin Pharmaceutical has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, BioMarin Pharmaceutical had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.75 beat BioMarin Pharmaceutical's score of 0.64 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioMarin Pharmaceutical beats Edgewise Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Edgewise Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EWTX vs. The Competition

Export

Metric	Edgewise Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.10B	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-24.50	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	9.19	15.45	10.46	6.33
Net Income	-$167.79M	-$22.86M	$3.49B	$358.33M
7 Day Performance	2.07%	-1.21%	0.59%	1.12%
1 Month Performance	-2.41%	-4.42%	-2.01%	-2.67%
1 Year Performance	217.81%	37.81%	18.09%	6.01%

Edgewise Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EWTX Edgewise Therapeutics	2.4456 of 5 stars	$45.32 -3.5%	$50.33 +11.1%	+191.8%	$5.10B	N/A	N/A	127	Options Volume
ASND Ascendis Pharma A/S	4.7241 of 5 stars	$270.09 -0.2%	$310.05 +14.8%	+18.7%	$16.88B	$814.57M	20.95	1,189	Analyst Downgrade
BBIO BridgeBio Pharma	3.5816 of 5 stars	$74.76 -0.1%	$101.53 +35.8%	+24.9%	$14.63B	$713.07M	N/A	400	Options Volume
EXEL Exelixis	2.4195 of 5 stars	$57.67 -2.3%	$50.07 -13.2%	+44.3%	$14.62B	$2.32B	18.14	1,077
SMMT Summit Therapeutics	2.3308 of 5 stars	$17.28 -1.8%	$24.82 +43.6%	-7.2%	$14.04B	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EWTX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. ASND, BBIO, EXEL, SMMT, and BMRN

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Summary

How does Edgewise Therapeutics compare to Exelixis?

Summary

How does Edgewise Therapeutics compare to Summit Therapeutics?

Summary

How does Edgewise Therapeutics compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. ASND, BBIO, EXEL, SMMT, and BMRN

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Does the media favor EWTX or ASND?

Do analysts rate EWTX or ASND?

Which has better valuation & earnings, EWTX or ASND?

Is EWTX or ASND more profitable?

Which has more volatility & risk, EWTX or ASND?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Do analysts recommend BBIO or EWTX?

Do institutionals & insiders believe in BBIO or EWTX?

Which has more volatility and risk, BBIO or EWTX?

Which has preferable valuation & earnings, BBIO or EWTX?

Does the media refer more to BBIO or EWTX?

Is BBIO or EWTX more profitable?

Summary

How does Edgewise Therapeutics compare to Exelixis?

Which has more risk and volatility, EWTX or EXEL?

Do analysts recommend EWTX or EXEL?

Which has stronger valuation and earnings, EWTX or EXEL?

Is EWTX or EXEL more profitable?

Do institutionals and insiders have more ownership in EWTX or EXEL?

Does the media favor EWTX or EXEL?

Summary

How does Edgewise Therapeutics compare to Summit Therapeutics?

Does the media favor SMMT or EWTX?

Which has more risk & volatility, SMMT or EWTX?

Which has preferable valuation & earnings, SMMT or EWTX?

Do institutionals & insiders hold more shares of SMMT or EWTX?

Is SMMT or EWTX more profitable?

Do analysts recommend SMMT or EWTX?

Summary

How does Edgewise Therapeutics compare to BioMarin Pharmaceutical?

Is BMRN or EWTX more profitable?

Do institutionals & insiders believe in BMRN or EWTX?

Which has more volatility & risk, BMRN or EWTX?

Do analysts prefer BMRN or EWTX?

Which has higher valuation & earnings, BMRN or EWTX?

Does the media prefer BMRN or EWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools